When used in conjuction with oncolytic viruses, erastin synergistically enhances antitumor immune responses and therapeutic efficacy by promoting the proliferation of activated dendritic cells and enhancing the activity of tumor-specific CD8+ T cells [126]. This evidence concerns the gene CD8A and neoplasm.